» Articles » PMID: 38238510

The Antihypertensive Action of C-phycocyanin is Related to the Prevention of Angiotensin II-caused Vascular Dysfunction in Chronic Kidney Disease

Abstract

C-phycocyanin (CPC) is a photosynthetic protein found in Arthrospira maxima with a nephroprotective and antihypertensive activity that can prevent the development of hemodynamic alterations caused by chronic kidney disease (CKD). However, the complete nutraceutical activities are still unknown. This study aims to determine if the antihypertensive effect of CPC is associated with preventing the impairment of hemodynamic variables through delaying vascular dysfunction. Twenty-four normotensive male Wistar rats were divided into four groups: (1) sham + 4 mL/kg/d vehicle (100 mM of phosphate buffer, PBS) administered by oral gavage (og), (2) sham + 100 mg/kg/d og of CPC, (3) CKD induced by 5/6 nephrectomy (CKD) + vehicle, (4) CKD + CPC. One week after surgery, the CPC treatment began and was administrated daily for four weeks. At the end treatment, animals were euthanized, and their thoracic aorta was used to determine the vascular function and expression of AT1, AT2, and Mas receptors. CKD-induced systemic arterial hypertension (SAH) and vascular dysfunction by reducing the vasorelaxant response of angiotensin 1-7 and increasing the contractile response to angiotensin II. Also, CKD increased the expression of the AT1 and AT2 receptors and reduced the Mas receptor expression. Remarkably, the treatment with CPC prevented SAH, renal function impairment, and vascular dysfunction in the angiotensin system. In conclusion, the antihypertensive activity of CPC is associated with avoiding changes in the expression of AT1, AT2, and Mas receptors, preventing vascular dysfunction development and SAH in rats with CKD.

Citing Articles

C-Phycoerythrin Prevents Chronic Kidney Disease-Induced Systemic Arterial Hypertension, Avoiding Oxidative Stress and Vascular Dysfunction in Remanent Functional Kidney.

Florencio-Santiago O, Blas-Valdivia V, Serrano-Contreras J, Rojas-Franco P, Escalona-Cardoso G, Paniagua-Castro N Mar Drugs. 2024; 22(8).

PMID: 39195453 PMC: 11355432. DOI: 10.3390/md22080337.

References
1.
Webster A, Nagler E, Morton R, Masson P . Chronic Kidney Disease. Lancet. 2016; 389(10075):1238-1252. DOI: 10.1016/S0140-6736(16)32064-5. View

2.
Terada Y, Yayama K . Angiotensin II-Induced Vasoconstriction via Rho Kinase Activation in Pressure-Overloaded Rat Thoracic Aortas. Biomolecules. 2021; 11(8). PMC: 8391281. DOI: 10.3390/biom11081076. View

3.
Chou Y, Chu T, Lin S . Role of renin-angiotensin system in acute kidney injury-chronic kidney disease transition. Nephrology (Carlton). 2018; 23 Suppl 4:121-125. DOI: 10.1111/nep.13467. View

4.
Bader M, Alenina N, Young D, Santos R, Touyz R . The Meaning of Mas. Hypertension. 2018; 72(5):1072-1075. PMC: 6217935. DOI: 10.1161/HYPERTENSIONAHA.118.10918. View

5.
Nowak K, Jovanovich A, Farmer-Bailey H, Bispham N, Struemph T, Malaczewski M . Vascular Dysfunction, Oxidative Stress, and Inflammation in Chronic Kidney Disease. Kidney360. 2020; 1(6):501-509. PMC: 7725223. DOI: 10.34067/kid.0000962019. View